These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 23417499)

  • 41. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
    Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
    J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Terminal ileum neuroendocrine incidentaloma in a patient with sporadic medullary thyroid carcinoma: findings from 18F-FDOPA PET/CT investigation.
    Imperiale A; Rust E; Boulanger C; Roedlich MN; Ollier JC; Schneegans O
    Clin Nucl Med; 2012 Aug; 37(8):e206-8. PubMed ID: 22785529
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors.
    Kubota K; Okasaki M; Minamimoto R; Miyata Y; Morooka M; Nakajima K; Sato T
    Ann Nucl Med; 2014 Dec; 28(10):1004-10. PubMed ID: 25179521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
    Shamim SA; Kumar A; Kumar R
    PET Clin; 2015 Jul; 10(3):411-21. PubMed ID: 26099675
    [TBL] [Abstract][Full Text] [Related]  

  • 46. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
    Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
    [No Abstract]   [Full Text] [Related]  

  • 47. A Prospective Comparative Study of 18 F-FDOPA PET/CT Versus 123 I-MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma.
    Sung C; Lee HS; Lee DY; Kim YI; Kim JE; Lee SJ; Oh SJ; Sung TY; Lee YM; Kim YH; Kim BJ; Koh JM; Lee SH; Ryu JS
    Clin Nucl Med; 2024 Jan; 49(1):27-36. PubMed ID: 38054497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PET imaging in neuroendocrine tumors: current status and future prospects.
    Basu S; Kumar R; Rubello D; Fanti S; Alavi A
    Minerva Endocrinol; 2008 Sep; 33(3):257-75. PubMed ID: 18846029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular imaging for neuroendocrine tumours.
    Antwi K; Nicolas G; Wild D; Christ E
    Swiss Med Wkly; 2019 Feb; 149():w20017. PubMed ID: 30852831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Best sensitivity of
    Testart Dardel N; Montravers F; Triviño-Ibañez E; Gauthé M; Houry S; Talbot JN
    Rev Esp Med Nucl Imagen Mol; 2016; 35(6):402-405. PubMed ID: 27246293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas.
    Taïeb D; Tessonnier L; Sebag F; Niccoli-Sire P; Morange I; Colavolpe C; De Micco C; Barlier A; Palazzo FF; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):580-6. PubMed ID: 18394015
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
    Ito T; Jensen RT
    Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):15-24. PubMed ID: 27875420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome.
    Weisbrod AB; Kitano M; Gesuwan K; Millo C; Herscovitch P; Nilubol N; Linehan WM; Kebebew E
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E613-7. PubMed ID: 22259055
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recurrence of a Pheochromocytoma With TNEM127 Mutation Negative on 18F-FDOPA and 18F-FDG but Positive on 123I-MIBG and 68Ga-DOTATOC Imaging.
    Cottereau AS; Garcia C; Dousset B; Libe R; Tenenbaum F
    Clin Nucl Med; 2022 Mar; 47(3):251-252. PubMed ID: 34507330
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Guideline for PET/CT imaging of neuroendocrine neoplasms with
    Bozkurt MF; Virgolini I; Balogova S; Beheshti M; Rubello D; Decristoforo C; Ambrosini V; Kjaer A; Delgado-Bolton R; Kunikowska J; Oyen WJG; Chiti A; Giammarile F; Sundin A; Fanti S
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1588-1601. PubMed ID: 28547177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
    Schiesser M; Veit-Haibach P; Muller MK; Weber M; Bauerfeind P; Hany T; Clavien PA
    Br J Surg; 2010 May; 97(5):691-7. PubMed ID: 20225244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
    Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L
    Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
    Panagiotidis E; Bomanji J
    PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.